+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anxiolytics Market - Global Forecast 2026-2032- Product Image
Anxiolytics Market - Global Forecast 2026-2032- Product Image
New

Anxiolytics Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 182 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5887787
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The anxiolytics market is experiencing significant shifts, driven by evolving clinical standards, regulatory adjustments, and operational imperatives. Senior executives need a clear, actionable analysis of the market’s direction to inform strategic planning and investment.

Market Snapshot

The anxiolytics market grew from USD 1.42 billion in 2025 to USD 1.54 billion in 2026. It is expected to continue growing at a CAGR of 7.53%, reaching USD 2.37 billion by 2032.

Scope & Segmentation

This report presents a detailed examination of the anxiolytics market by key dimensions, providing practical intelligence for senior decision-makers:

  • Drug Classes: Azapirones, Benzodiazepines (differentiated by duration of action), Selective Serotonin Reuptake Inhibitors, Serotonin Norepinephrine Reuptake Inhibitors
  • Routes of Administration: Oral, intranasal, parenteral (including intramuscular, intravenous, subcutaneous)
  • Formulation Types: Capsule (hard and soft gelatin), injection, oral suspension, tablet (controlled and immediate release)
  • Distribution Channels: Hospital pharmacy, retail pharmacy, online pharmacy
  • End Users: Hospitals, clinics, homecare settings
  • Regions: Americas, Europe Middle East & Africa, Asia-Pacific

Technological innovation is further influencing the market through formulation science, digital therapeutics integration, and advanced manufacturing strategies that prioritize supply chain resilience.

Anxiolytics Market: Key Takeaways

  • The anxiolytics market is shaped by the interplay between mature therapies and emerging modalities designed to enhance safety and dosing precision.
  • Stakeholders see increased operational complexity due to payer demands for real-world outcomes and tighter regulatory oversight of post-approval safety.
  • Formulation choices—such as rapid-acting intranasal or controlled release oral therapies—impact adherence, clinical adoption, and cost-to-serve structures.
  • Growth in digital therapeutics and integrated care models is supporting more personalized and cost-effective anxiety management pathways.
  • Regional differences in regulatory frameworks and payer systems require manufacturers to align evidence generation, pricing, and distribution strategies accordingly.
  • Competitive advantage goes to those investing in both operational agility and cross-sector partnerships that accelerate market entry and reinforce supply stability.

Tariff Impact on Anxiolytics Supply Chain

The introduction of United States tariffs in 2025 has intensified cost volatility across supply chains that support anxiolytic therapies. Manufacturers have responded by diversifying suppliers, exploring nearshoring initiatives, and renegotiating inventory and procurement strategies. This environment has driven organizations toward new manufacturing footprints and deeper collaboration with contract manufacturing organizations. Downstream, shifts in payer and provider behavior are visible as acquisition costs affect formulary preferences and patient access models. Transparent cost-serve analytics and robust scenario planning have become essential for anticipating reimbursement impacts and sustaining patient availability.

Methodology & Data Sources

Analysis draws on primary interviews with clinicians, supply chain experts, and decision-makers, alongside systematic review of peer-reviewed literature, regulatory publications, and clinical trial data. Qualitative and quantitative methods were triangulated, with independent cross-validation and advisor review to ensure actionable, evidence-based findings underpin every recommendation.

Anxiolytics Market: Why This Report Matters

  • Enables senior leaders to recalibrate portfolios and channel investments toward therapies and technologies most aligned with evolving market access requirements.
  • Supports manufacturing and distribution teams by mapping operational risks and opportunities created by regulatory changes, tariff actions, and regional market shifts.
  • Offers targeted, practice-driven insights for aligning R&D, regulatory, and commercial teams to sustain competitiveness in a changing anxiolytics environment.

Conclusion

As clinical, operational, and policy factors reshape the anxiolytics market, organizations that anticipate change and align resources across the value chain will achieve sustainable access and commercial success. Proactive adaptation secures long-term relevance for patients and partners alike.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Anxiolytics Market, by Drug Class
8.1. Azapirones
8.2. Benzodiazepines
8.2.1. Intermediate Acting
8.2.2. Long Acting
8.2.3. Short Acting
8.3. Selective Serotonin Reuptake Inhibitors
8.3.1. Escitalopram
8.3.2. Paroxetine
8.3.3. Sertraline
8.4. Serotonin Norepinephrine Reuptake Inhibitors
8.4.1. Duloxetine
8.4.2. Venlafaxine
9. Anxiolytics Market, by Route Of Administration
9.1. Intranasal
9.2. Oral
9.3. Parenteral
9.3.1. Intramuscular
9.3.2. Intravenous
9.3.3. Subcutaneous
10. Anxiolytics Market, by Form
10.1. Capsule
10.1.1. Hard Gelatin
10.1.2. Soft Gelatin
10.2. Injection
10.3. Oral Suspension
10.4. Tablet
10.4.1. Controlled Release
10.4.2. Immediate Release
11. Anxiolytics Market, by Distribution Channel
11.1. Hospital Pharmacy
11.2. Online Pharmacy
11.3. Retail Pharmacy
12. Anxiolytics Market, by End User
12.1. Clinics
12.2. Homecare Settings
12.3. Hospitals
13. Anxiolytics Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Anxiolytics Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Anxiolytics Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Anxiolytics Market
17. China Anxiolytics Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. AbbVie Inc.
18.6. Accord Healthcare US
18.7. Akorn Operating Company LLC
18.8. Alvogen
18.9. Amneal Pharmaceuticals LLC
18.10. Apotex Inc.
18.11. AstraZeneca PLC
18.12. Bausch Health Companies Inc.
18.13. Dellwich Healthcare LLP
18.14. Eli Lilly and Company
18.15. F. Hoffmann-La Roche Ltd.
18.16. GlaxoSmithKline PLC
18.17. H. Lundbeck A/S
18.18. Hameln Pharma GmbH
18.19. Hikma Pharmaceuticals PLC
18.20. Johnson & Johnson Services, Inc.
18.21. Lifecare Neuro Products Limited
18.22. Lifegenix
18.23. Neurocon Inc.
18.24. Noreva Biotech
18.25. Novartis AG
18.26. Pfizer Inc.
18.27. Sanofi S.A.
18.28. Sun Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL ANXIOLYTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ANXIOLYTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ANXIOLYTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ANXIOLYTICS MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANXIOLYTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ANXIOLYTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANXIOLYTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES ANXIOLYTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA ANXIOLYTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ANXIOLYTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANXIOLYTICS MARKET SIZE, BY AZAPIRONES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ANXIOLYTICS MARKET SIZE, BY INTERMEDIATE ACTING, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ANXIOLYTICS MARKET SIZE, BY INTERMEDIATE ACTING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ANXIOLYTICS MARKET SIZE, BY INTERMEDIATE ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ANXIOLYTICS MARKET SIZE, BY LONG ACTING, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ANXIOLYTICS MARKET SIZE, BY LONG ACTING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ANXIOLYTICS MARKET SIZE, BY LONG ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ANXIOLYTICS MARKET SIZE, BY SHORT ACTING, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ANXIOLYTICS MARKET SIZE, BY SHORT ACTING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ANXIOLYTICS MARKET SIZE, BY SHORT ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ANXIOLYTICS MARKET SIZE, BY ESCITALOPRAM, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ANXIOLYTICS MARKET SIZE, BY ESCITALOPRAM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ANXIOLYTICS MARKET SIZE, BY ESCITALOPRAM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ANXIOLYTICS MARKET SIZE, BY PAROXETINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ANXIOLYTICS MARKET SIZE, BY PAROXETINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ANXIOLYTICS MARKET SIZE, BY PAROXETINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ANXIOLYTICS MARKET SIZE, BY SERTRALINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ANXIOLYTICS MARKET SIZE, BY SERTRALINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ANXIOLYTICS MARKET SIZE, BY SERTRALINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ANXIOLYTICS MARKET SIZE, BY DULOXETINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ANXIOLYTICS MARKET SIZE, BY DULOXETINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ANXIOLYTICS MARKET SIZE, BY DULOXETINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ANXIOLYTICS MARKET SIZE, BY VENLAFAXINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ANXIOLYTICS MARKET SIZE, BY VENLAFAXINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ANXIOLYTICS MARKET SIZE, BY VENLAFAXINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ANXIOLYTICS MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ANXIOLYTICS MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ANXIOLYTICS MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ANXIOLYTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ANXIOLYTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ANXIOLYTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ANXIOLYTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ANXIOLYTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ANXIOLYTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ANXIOLYTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ANXIOLYTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ANXIOLYTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ANXIOLYTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ANXIOLYTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ANXIOLYTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ANXIOLYTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ANXIOLYTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ANXIOLYTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ANXIOLYTICS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ANXIOLYTICS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ANXIOLYTICS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ANXIOLYTICS MARKET SIZE, BY HARD GELATIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ANXIOLYTICS MARKET SIZE, BY HARD GELATIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ANXIOLYTICS MARKET SIZE, BY HARD GELATIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ANXIOLYTICS MARKET SIZE, BY SOFT GELATIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ANXIOLYTICS MARKET SIZE, BY SOFT GELATIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ANXIOLYTICS MARKET SIZE, BY SOFT GELATIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ANXIOLYTICS MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ANXIOLYTICS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ANXIOLYTICS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ANXIOLYTICS MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ANXIOLYTICS MARKET SIZE, BY ORAL SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ANXIOLYTICS MARKET SIZE, BY ORAL SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ANXIOLYTICS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL ANXIOLYTICS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ANXIOLYTICS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL ANXIOLYTICS MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL ANXIOLYTICS MARKET SIZE, BY CONTROLLED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL ANXIOLYTICS MARKET SIZE, BY CONTROLLED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL ANXIOLYTICS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL ANXIOLYTICS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL ANXIOLYTICS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL ANXIOLYTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL ANXIOLYTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL ANXIOLYTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL ANXIOLYTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL ANXIOLYTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL ANXIOLYTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL ANXIOLYTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL ANXIOLYTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL ANXIOLYTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL ANXIOLYTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL ANXIOLYTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL ANXIOLYTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL ANXIOLYTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL ANXIOLYTICS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL ANXIOLYTICS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL ANXIOLYTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL ANXIOLYTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL ANXIOLYTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL ANXIOLYTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. AMERICAS ANXIOLYTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 111. AMERICAS ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 112. AMERICAS ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 113. AMERICAS ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 114. AMERICAS ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 115. AMERICAS ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 116. AMERICAS ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 117. AMERICAS ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 118. AMERICAS ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 119. AMERICAS ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 120. AMERICAS ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 121. AMERICAS ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 122. NORTH AMERICA ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. NORTH AMERICA ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 124. NORTH AMERICA ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 125. NORTH AMERICA ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 126. NORTH AMERICA ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 127. NORTH AMERICA ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 128. NORTH AMERICA ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 129. NORTH AMERICA ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 130. NORTH AMERICA ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 131. NORTH AMERICA ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 132. NORTH AMERICA ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 133. NORTH AMERICA ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 134. LATIN AMERICA ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. LATIN AMERICA ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 136. LATIN AMERICA ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 137. LATIN AMERICA ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 138. LATIN AMERICA ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 139. LATIN AMERICA ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 140. LATIN AMERICA ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 141. LATIN AMERICA ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 142. LATIN AMERICA ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 143. LATIN AMERICA ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 144. LATIN AMERICA ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 145. LATIN AMERICA ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANXIOLYTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 158. EUROPE ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 159. EUROPE ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 160. EUROPE ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 161. EUROPE ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 162. EUROPE ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 163. EUROPE ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 164. EUROPE ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 165. EUROPE ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 166. EUROPE ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 167. EUROPE ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 168. EUROPE ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 169. EUROPE ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 170. MIDDLE EAST ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 171. MIDDLE EAST ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 172. MIDDLE EAST ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 173. MIDDLE EAST ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 174. MIDDLE EAST ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 175. MIDDLE EAST ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 176. MIDDLE EAST ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 177. MIDDLE EAST ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 178. MIDDLE EAST ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 179. MIDDLE EAST ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 180. MIDDLE EAST ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 181. MIDDLE EAST ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 182. AFRICA ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 183. AFRICA ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 184. AFRICA ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 185. AFRICA ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 186. AFRICA ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 187. AFRICA ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 188. AFRICA ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 189. AFRICA ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 190. AFRICA ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 191. AFRICA ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 192. AFRICA ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 193. AFRICA ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 194. ASIA-PACIFIC ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 195. ASIA-PACIFIC ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 196. ASIA-PACIFIC ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 197. ASIA-PACIFIC ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 198. ASIA-PACIFIC ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 199. ASIA-PACIFIC ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 200. ASIA-PACIFIC ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 201. ASIA-PACIFIC ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 202. ASIA-PACIFIC ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 203. ASIA-PACIFIC ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 204. ASIA-PACIFIC ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 205. ASIA-PACIFIC ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 206. GLOBAL ANXIOLYTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 207. ASEAN ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 208. ASEAN ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 209. ASEAN ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 210. ASEAN ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 211. ASEAN ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 212. ASEAN ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 213. ASEAN ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 214. ASEAN ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 215. ASEAN ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 216. ASEAN ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 217. ASEAN ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 218. ASEAN ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 219. GCC ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 220. GCC ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 221. GCC ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 222. GCC ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 223. GCC ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 224. GCC ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 225. GCC ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 226. GCC ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 227. GCC ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 228. GCC ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 229. GCC ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 230. GCC ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 231. EUROPEAN UNION ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 232. EUROPEAN UNION ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 240. EUROPEAN UNION ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 241. EUROPEAN UNION ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 243. BRICS ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 244. BRICS ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 245. BRICS ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 246. BRICS ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 247. BRICS ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 248. BRICS ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 249. BRICS ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 250. BRICS ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 251. BRICS ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 252. BRICS ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 253. BRICS ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 254. BRICS ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 255. G7 ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 256. G7 ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 257. G7 ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 258. G7 ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 259. G7 ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 260. G7 ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 261. G7 ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 262. G7 ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 263. G7 ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 264. G7 ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 265. G7 ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 266. G7 ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 267. NATO ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 268. NATO ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 269. NATO ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 270. NATO ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 271. NATO ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 272. NATO ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 273. NATO ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 274. NATO ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 275. NATO ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 276. NATO ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 277. NATO ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 278. NATO ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 279. GLOBAL ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 280. UNITED STATES ANXIOLYTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 281. UNITED STATES ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 282. UNITED STATES ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 283. UNITED STATES ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 284. UNITED STATES ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 285. UNITED STATES ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 286. UNITED STATES ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 287. UNITED STATES ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 288. UNITED STATES ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 289. UNITED STATES ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 290. UNITED STATES ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 291. UNITED STATES ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 292. CHINA ANXIOLYTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 293. CHINA ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 294. CHINA ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
TABLE 295. CHINA ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 296. CHINA ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 297. CHINA ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 298. CHINA ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 299. CHINA ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
TABLE 300. CHINA ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
TABLE 301. CHINA ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
TABLE 302. CHINA ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 303. CHINA ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Anxiolytics market report include:
  • AbbVie Inc.
  • Accord Healthcare US
  • Akorn Operating Company LLC
  • Alvogen
  • Amneal Pharmaceuticals LLC
  • Apotex Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Dellwich Healthcare LLP
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Hameln Pharma GmbH
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Lifecare Neuro Products Limited
  • Lifegenix
  • Neurocon Inc.
  • Noreva Biotech
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages182
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.54 Billion
Forecasted Market Value ( USD ) by 2032 $ 2.37 Billion
Compound Annual Growth Rate7.5%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Anxiolytics - Global Strategic Business Report - Product Image

Anxiolytics - Global Strategic Business Report

  • Report
  • 108 Pages
  • Global
From
2025 Global Forecast for Anxiolytics Market (2026-2031 Outlook)-High Tech Outlook Report - Product Image

2025 Global Forecast for Anxiolytics Market (2026-2031 Outlook)-High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From
Anxiety Drugs Market - Global Forecast 2026-2032 - Product Image

Anxiety Drugs Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Generalized Anxiety Disorder - Pipeline Insight, 2025 - Product Image

Generalized Anxiety Disorder - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Bromazepam Market - Global Forecast 2026-2032 - Product Image

Bromazepam Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From

About the Anxiolytic Market

Anxiolytic drugs, also known as anti-anxiety drugs, are a class of medications used to treat anxiety disorders. These drugs work by altering the levels of certain neurotransmitters in the brain, such as serotonin and dopamine, to reduce feelings of fear and anxiety. Commonly prescribed anxiolytics include benzodiazepines, selective serotonin reuptake inhibitors (SSRIs), and tricyclic antidepressants. These drugs are used to treat a variety of anxiety disorders, including generalized anxiety disorder, panic disorder, and social anxiety disorder. Anxiolytics are widely prescribed and are generally considered safe and effective when used as directed. However, they can be habit-forming and may cause side effects such as drowsiness, dizziness, and confusion. As such, they should only be used under the supervision of a doctor. Some of the major companies in the anxiolytic market include Pfizer, GlaxoSmithKline, Eli Lilly, and AstraZeneca. These companies produce a variety of anxiolytic drugs, including benzodiazepines, SSRIs, and tricyclic antidepressants. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.